

Alloimmune disorders of pregnancy

Anaemia, thrombocytopenia and neutropenia in the fetus and newborn

Collectively known as the alloimmune cytopenias, haemolytic disease of the fetus and newborn, alloimmune thrombocytopenia and alloimmune neutropenia are all consequences of maternal immunization to fetal blood cells. The effective prevention, diagnosis and management of these disorders has become a team effort involving haematologists, obstetricians, paediatricians, immunologists, laboratory technicians, midwives and research scientists. This book has been written by experts in their respective fields to bring together the issues of pathogenesis, epidemiology, prevention, diagnosis and clinical management. This comprehensive but accessible account is extensively cross-referenced to emphasize the links between pathogenesis and clinical sequelae, between epidemiology and the rationale for screening programmes, and between diagnosis and therapeutic intervention.

This is an authoritative overview suitable for trainees in obstetrics, maternal and fetal medicine, transfusion medicine and clinical immunology.

Dr Andrew Hadley is Division Manager at the International Blood Group Reference Laboratory and Senior Scientist at the Bristol Institute for Transfusion Sciences, University of Bristol.

Professor Peter Soothill is Professor of Maternal and Fetal Medicine and Head of the Department of Obstetrics and Gynaecology, St Michael's Hospital and University of Bristol.

Cambridge University Press
0521018048 - Alloimmune Disorders of Pregnancy Anaemia, Thrombocytopenia and Neutropenia in the Fetus and Newborn
Edited by Andrew G Hadley and Peter Soothill
Frontmatter
[More information](#)

Alloimmune disorders of pregnancy

Anaemia, thrombocytopenia and
neutropenia in the fetus and newborn

Edited by

Andrew G Hadley

International Blood Group Reference Laboratory,
Southmead Road, Bristol

and

Peter Soothill

Department of Maternal and Fetal Medicine,
St Michael's Hospital,
Southwell Street, Bristol



CAMBRIDGE
UNIVERSITY PRESS

Cambridge University Press
0521018048 - Alloimmune Disorders of Pregnancy Anaemia, Thrombocytopenia and Neutropenia in the Fetus and Newborn
Edited by Andrew G Hadley and Peter Soothill
Frontmatter
[More information](#)

CAMBRIDGE UNIVERSITY PRESS
Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, São Paulo

Cambridge University Press
The Edinburgh Building, Cambridge CB2 2RU, UK

Published in the United States of America by Cambridge University Press, New York

www.cambridge.org
Information on this title: www.cambridge.org/9780521781206

© Cambridge University Press 2002

This book is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2002
This digitally printed first paperback version 2005

A catalogue record for this publication is available from the British Library

Library of Congress Cataloguing in Publication data

Alloimmune disorders of pregnancy: anaemia, thrombocytopenia, and neutropenia in the fetus and newborn / [edited by] Andrew G Hadley and Peter Soothill.
p. cm.

Includes bibliographical references and index.

ISBN 0 521 78120 5 (hardback)

1. Blood diseases in pregnancy. 2. Fetus – Diseases. 3. Pregnancy – Complications. I. Hadley, Andrew G, 1957– II. Soothill, Peter, 1957–

[DNLM: 1. Anemia, Hemolytic, Autoimmune – Infant, Newborn. 2. Fetal Diseases. 3. Infant, Newborn, Diseases. 4. Neutropenia – Infant, Newborn. 5. Pregnancy Complications. 6. Prenatal Diagnosis. 7. Thrombocytopenia – Infant, Newborn. WS 420 A441 2002]

RG572.A456 2002

618.3'261–dc21 2001025639

ISBN-13 978-0-521-78120-6 hardback

ISBN-10 0-521-78120-5 hardback

ISBN-13 978-0-521-01804-3 paperback

ISBN-10 0-521-01804-8 paperback

Every effort has been made in preparing this book to provide accurate and up-to-date information which is in accord with accepted standards and practice at the time of publication. Nevertheless, the authors, editors and publisher can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors and publisher therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.

Contents

	<i>List of contributors</i>	<i>page</i> xv
	<i>Preface</i>	xvii
	<i>Foreword</i>	xix
	<i>List of abbreviations</i>	xxi
1	Pathophysiology of the alloimmune cytopenias	1
	Andrew G Hadley and Craig Turner	
	1.1 Maternal alloimmunization	1
	1.1.1 Some key events in the humoral immune response	1
	1.1.2 The maternal alloimmune response to fetal red cells	4
	1.1.3 The maternal alloimmune response to fetal platelets	5
	1.1.4 The maternal alloimmune response to fetal neutrophils	6
	1.2 Transfer of IgG to the fetus	6
	1.3 The immune destruction of blood cells in the fetus	7
	1.3.1 IgG and Fc γ receptors	8
	1.3.2 The immune destruction of fetal red cells	8
	1.3.3 The immune destruction of fetal platelets	12
	1.3.4 The immune destruction of fetal neutrophils	14
	1.4 Conclusions	14
	1.5 References	14
2	Blood group antibodies in haemolytic disease of the fetus and newborn	21
	Geoff Daniels	
	2.1 Introduction	21
	2.2 Blood group terminology	21
	2.3 The genetics of blood groups	24
	2.4 The effect of antigen expression on the pathogenicity and severity of HDFN	25
	2.5 Antibodies that most commonly cause moderate or severe HDFN	27

vi	Contents	
	2.5.1 Anti-D	27
	2.5.2 Other antibodies to Rh-system antigens	30
	2.5.3 Anti-K	31
	2.5.4 Other antibodies to Kell-system antigens	32
	2.6 Antibodies that most commonly cause mild HDFN	33
	2.6.1 The ABO system	33
	2.7 Antibodies that rarely cause HDFN	34
	2.7.1 MNS system	34
	2.7.2 Duffy system	35
	2.7.3 Kidd system	35
	2.7.4 Diego system	35
	2.7.5 Colton system	36
	2.7.6 Other antigens	36
	2.8 Antibodies that do not cause HDFN	36
	2.9 Conclusions	37
	2.10 References	37
3	Basis and practice of screening for haemolytic disease of the fetus and newborn	41
	Geoff Poole	
	3.1 Introduction	41
	3.2 The basis of screening for HDFN	41
	3.3 Antenatal screening tests performed in the blood transfusion laboratory	42
	3.3.1 Antiglobulin methods	42
	3.3.2 Enzyme methods	46
	3.3.3 The choice of red cells for screening tests	47
	3.3.4 Manual versus automated methods	48
	3.3.5 Timing of screening tests	49
	3.4 The identification of red cell alloantibodies	50
	3.4.1 Methods	50
	3.4.2 The principles of antibody identification	51
	3.4.3 Difficulties encountered in antibody identification	54
	3.4.4 Implications of detecting a red cell alloantibody during pregnancy	55
	3.5 Paternal and fetal phenotyping	56
	3.5.1 Paternal phenotype	56
	3.5.2 Fetal phenotype	57
	3.6 Laboratory tests immediately following delivery	58
	3.7 References	58

vii	Contents	
4	Epidemiology and screening for alloimmune thrombocytopenia	61
	Lorna M Williamson and Michael F Murphy	
	4.1 Background	61
	4.2 Epidemiology and the natural history of alloimmune thrombocytopenia	62
	4.2.1 The incidence of maternal alloimmunization	62
	4.2.2 The incidence of fetal thrombocytopenia due to maternal alloimmunization	62
	4.2.3 The incidence of intracranial haemorrhage and other sequelae	63
	4.2.4 The influence of obstetric history on clinical outcome	63
	4.3 Criteria for antenatal screening for alloimmune thrombocytopenia	64
	4.3.1 The condition should be an important health problem	64
	4.3.2 The epidemiology of the condition should be known	65
	4.3.3 The natural history of the condition should be understood	65
	4.3.4 There should be a recognized latent period or early asymptomatic stage	65
	4.3.5 All the cost-effective primary prevention interventions should have been implemented as far as practicable	66
	4.3.6 There should be a simple, safe, precise and validated screening test	66
	4.3.7 The distribution of test values in the target population should be known and a suitable cut-off level defined and agreed	66
	4.3.8 The test should be acceptable to the population	67
	4.3.9 There should be an agreed policy on the further diagnostic investigation of individuals with a positive result and on the choices available to those individuals	67
	4.3.10 There should be an effective treatment or intervention for patients identified through early detection	67
	4.3.11 There should be agreed evidence-based policies covering which individuals should be offered treatment and the appropriate treatment to be offered	69
	4.3.12 Clinical management of the condition and patient outcomes should be optimized by all health providers prior to participation in a screening programme	69
	4.4 The cost-effectiveness of a screening programme	69
	4.5 Conclusions	70
	4.6 References	70
5	Principles of antibody-mediated immune suppression and the prevention of maternal RhD alloimmunization	73
	Belinda Kumpel	
	5.1 Haemolytic disease of the fetus and newborn due to anti-D	73
	5.2 Experimental studies on the prevention of RhD immunization	74

viii	Contents	
	5.3 Clinical studies on the efficacy of RhD prophylaxis	75
	5.3.1 Dose of anti-D	76
	5.3.2 The current situation	77
	5.4 Characteristics and requirements of RhD prophylaxis	78
	5.4.1 Ratio of antibody to antigen required for suppression	78
	5.4.2 Relationship of red cell clearance to antibody-mediated immune suppression	78
	5.4.3 Protection afforded by ABO antibodies	79
	5.4.4 Role of the spleen in RhD prophylaxis	79
	5.4.5 Timing of passive anti-D	79
	5.4.6 Time of detection of anti-D response	79
	5.4.7 Effect of passive anti-D on subsequent immunization	80
	5.4.8 Effect of passive anti-D on an established primary response	80
	5.4.9 Role of anti-D Fc fragments	80
	5.4.10 Epitope specificity	80
	5.5 Theories of the mechanism of action of prophylactic anti-D	81
	5.5.1 Inhibition of B cells by crosslinking heterologous receptors	81
	5.5.2 Anti-idiotypic antibodies	83
	5.5.3 Masking of antigen sites	84
	5.5.4 Clearance and destruction of D-positive red cells	84
	5.6 Development of monoclonal anti-D for RhD prophylaxis	84
	5.6.1 Production of monoclonal anti-D	85
	5.6.2 Half-lives of monoclonal anti-D	85
	5.6.3 In vitro functional activity of monoclonal anti-D	86
	5.6.4 In vivo red cell clearance mediated by monoclonal anti-D	86
	5.6.5 Suppression of the anti-D response by monoclonal anti-D	88
	5.7 References	88
6	The clinical application of anti-D prophylaxis	97
	Stan Urbaniak	
	6.1 Epidemiology	97
	6.1.1 Causes and incidence of alloimmunization	97
	6.1.2 Ethnic groups	97
	6.1.3 Use of D-negative transfusions for young women	97
	6.1.4 Relative importance of anti-D before and after the introduction of anti-D prophylaxis programmes	98
	6.2 Prophylaxis programmes	98
	6.2.1 Suppression of the immune response	98
	6.2.2 Recommendations and guidelines	99
	6.2.3 Effectiveness in Caucasian populations	101

ix	Contents	
	6.2.4 Reasons for continued failures	101
	6.2.5 Anti-D immunization during pregnancy	102
	6.2.6 Antenatal administration of anti-D immunoglobulin	102
	6.2.7 Anti-D immunoglobulin use on women with weak D or partial D	104
	6.2.8 Anti-D immunoglobulin use after the accidental transfusion of D-positive red cells	104
	6.3 Detection of fetal red cells in the maternal circulation	105
	6.3.1 The Kleihauer–Betke acid-elution test	106
	6.3.2 Flow cytometry	106
	6.3.3 Serological tests of fetomaternal haemorrhage	107
	6.3.4 Calculating the size of fetomaternal haemorrhage	107
	6.4 Fetomaternal haemorrhage and dose of anti-D immunoglobulin	108
	6.4.1 Fetomaternal haemorrhage at delivery	108
	6.4.2 Bleeding during pregnancy	108
	6.4.3 Spontaneous fetomaternal haemorrhage during first, second and third trimesters	109
	6.4.4 Other significant events during pregnancy	110
	6.4.5 Fetomaternal haemorrhage due to medical procedures	110
	6.4.6 Calculation of the required dose of anti-D	111
	6.5 Procurement of hyperimmune anti-D	112
	6.5.1 Identification, recruitment, boosting and accreditation of donors	112
	6.5.2 Manufacture of anti-D immunoglobulin and safety considerations	113
	6.6 Economics of prophylaxis programmes	114
	6.6.1 Cost-effectiveness of antenatal versus postnatal prophylaxis	114
	6.7 Future developments	115
	6.8 References	116
7	Fetal genotyping	121
	Neil D Avent	
	7.1 Introduction	121
	7.2 The polymerase chain reaction	121
	7.2.1 Principle of the polymerase chain reaction	121
	7.2.2 Polymerase chain reaction – restriction fragment length polymorphism analysis	122
	7.2.3 Allele-specific primer amplification	122
	7.3 PCR-based typing for clinically significant blood groups	124
	7.3.1 The Rh system	125
	7.3.2 Kell system	130
	7.3.3 Duffy system	131
	7.3.4 Kidd system	132
	7.3.5 ABO system	132

x	Contents	
	7.4 Noninvasive testing	133
	7.4.1 Detection of fetal RHD targets in genomic DNA extracted from fetal leukocytes in maternal blood	133
	7.4.2 The detection of fetal RhD cDNA derived from RNA extracted from maternal blood	133
	7.4.3 Detection of fetal RHD targets in genomic DNA extracted from maternal plasma	134
	7.5 Future perspectives	134
	7.6 References	135
8	Laboratory assays to determine the severity of haemolytic disease of the fetus and newborn	141
	Andrew G Hadley	
	8.1 Introduction	141
	8.2 Serological assays	141
	8.3 Quantitative assays	144
	8.4 Cellular assays	144
	8.4.1 The K lymphocyte-mediated ADCC assay	145
	8.4.2 The monocyte-mediated ADCC assay	146
	8.4.3 The monocyte monolayer assay	146
	8.4.4 The chemiluminescence test	147
	8.5 A strategy for antenatal testing	148
	8.6 References	149
9	Assessing the severity of haemolytic disease of the fetus and newborn: clinical aspects	153
	Sherif Abdel-Fattah and Peter Soothill	
	9.1 Introduction	153
	9.2 Noninvasive assessment	153
	9.2.1 Previous obstetric history	153
	9.2.2 Antibody levels	154
	9.2.3 Ultrasound findings	156
	9.2.4 Fetal heart rate monitoring	158
	9.2.5 Fetal Doppler ultrasonography	159
	9.3 Invasive testing	163
	9.3.1 Amniocentesis	163
	9.3.2 Fetal blood sampling	165
	9.4 Conclusions	167
	9.5 References	167

xi	Contents	
10	Antenatal therapy for haemolytic disease of the fetus and newborn	173
	Kenneth J Moise Jr and Paul W Whitecar	
10.1	Introduction	173
10.2	Plasmapheresis and intravenous immune globulin	173
10.2.1	Plasmapheresis	173
10.2.2	Intravenous immunoglobulin	175
10.3	Intrauterine transfusion	178
10.3.1	History	178
10.3.2	Access site	179
10.3.3	Method of transfusion	180
10.3.4	Amount to transfuse	181
10.3.5	The severely anaemic fetus	183
10.3.6	Adjunctive measures	183
10.3.7	Outcome	184
10.4	Red cells for transfusion	188
10.5	Experimental therapy	190
10.5.1	Immunoabsorption	190
10.5.2	Oral tolerance	191
10.5.3	Chemotherapeutic agents	191
10.5.4	Sensitization to paternal leukocyte antigens	192
10.6	Timing of delivery	193
10.7	Conclusion	193
10.8	References	193
11	Neonatal therapy for haemolytic disease of the newborn	203
	Glynn Russell and Nic Goulden	
11.1	Features of haemolytic disease in the neonate	203
11.1.1	Hydrops	203
11.1.2	Neonatal jaundice	204
11.1.3	Persistent anaemia	204
11.2	Laboratory diagnosis	204
11.3	General neonatal management	205
11.3.1	Communication	205
11.3.2	Resuscitation	205
11.4	Treatment of hydrops	206
11.5	Treatment of anaemia	206
11.5.1	Blood transfusion	206
11.5.2	Influence of fetal transfusions	209

xii	Contents	
	11.5.3 Indications for transfusion	209
	11.6 Treatment of neonatal jaundice	210
	11.6.1 Phototherapy	210
	11.6.2 Exchange blood transfusion	210
	11.6.3 An integrated approach to treating neonatal jaundice	212
	11.7 Experimental treatments	214
	11.8 References	214
12	The diagnosis of alloimmune thrombocytopenia	219
	Andrew G Hadley	
	12.1 Clinical aspects of diagnosis	219
	12.2 Platelet antigen systems	220
	12.2.1 Platelet antigens on glycoprotein IIb/IIIa	220
	12.2.2 Platelet antigens on glycoprotein Ia/IIa	221
	12.2.3 Platelet antigens on glycoprotein Ib/IX/V	221
	12.3 Platelet antibody specificities involved in alloimmune thrombocytopenia	221
	12.4 Laboratory diagnosis of alloimmune thrombocytopenia	224
	12.4.1 Haematology	224
	12.4.2 Assays for the detection of antiplatelet antibodies	225
	12.4.3 DNA-based genotyping	227
	12.4.4 Antibody characteristics and disease severity	228
	12.5 Future perspectives	228
	12.6 References	229
13	The immunological diagnosis of alloimmune neutropenia	235
	Geoff Lucas	
	13.1 Introduction	235
	13.2 Pathophysiology and clinical history	235
	13.2.1 Immunogenicity of fetal neutrophils	235
	13.2.2 Clinical manifestations and haematological findings	235
	13.2.3 Differential diagnosis	236
	13.3 The structure and function of antigens involved in alloimmune neutropenia	238
	13.3.1 Nomenclature	238
	13.3.2 Granulocyte-specific antigens	239
	13.3.3 'Shared' antigens	243
	13.3.4 Antibody specificities involved in alloimmune neutropenia	244
	13.3.5 The function of granulocyte antigens	244
	13.4 Laboratory diagnosis of alloimmune neutropenia	245
	13.4.1 Assays for granulocyte antibodies	245

xiii	Contents	
	13.4.2 Role of crossmatching and parental typing	247
	13.4.3 Granulocyte antigen typing	247
	13.5 References	248
14	Fetal and neonatal treatment of alloimmune thrombocytopenia	253
	Michael F Murphy, Rachel Rayment, David Allen and David Roberts	
	14.1 Introduction	253
	14.2 Neonatal management of alloimmune thrombocytopenia	254
	14.2.1 Platelet transfusion	254
	14.2.2 Intravenous immunoglobulin	256
	14.2.3 Monitoring of the effectiveness of neonatal treatment	257
	14.3 Antenatal management of alloimmune thrombocytopenia	257
	14.3.1 Fetal blood sampling	258
	14.3.2 Maternal treatment	259
	14.3.3 Fetal platelet transfusion	263
	14.3.4 Serial fetal platelet transfusions compared with maternal administration of high-dose intravenous immunoglobulin	267
	14.3.5 Timing of the initial fetal blood sample	268
	14.3.6 Strategy for the antenatal management of pregnancies at risk of very early intracranial haemorrhage	269
	14.4 Preparation of platelet concentrates for transfusion in cases of alloimmune thrombocytopenia	270
	14.4.1 Provision of HPA-typed platelets for neonates with alloimmune thrombocytopenia	270
	14.4.2 Identification and recruitment of HPA-1a-negative and HPA-5b-negative donors	270
	14.4.3 Preparation of platelet concentrates for fetal transfusions	271
	14.5 Future directions	272
	14.6 References	274
	<i>Index</i>	279

Contributors

Sherif Abdel-Fattah
Clinical Research Fellow, Fetal Medicine
Research Unit, St Michael’s Hospital,
Southwell Street, Bristol, BS2 8EG, UK

David Allen
Head of the Platelet Immunology
Laboratory, National Blood Service, John
Radcliffe Hospital, Oxford, OX3 9DU, UK
dave.allen@nbs.nhs.uk

Neil D Avent
Senior Lecturer, University of the West of
England, Coldharbour Lane, Bristol, BS16
1QY, UK
neil.avent@uwe.ac.uk

Geoff Daniels
Senior Research Fellow, Bristol Institute for
Transfusion Sciences, Southmead Road,
Bristol, BS10 5ND, UK
geoff.daniels@nbs.nhs.uk

Nic Goulden
Consultant Senior Lecturer in Paediatric
Haematology, The Bristol Children’s
Hospital, St Michael’s Hill, Bristol, BS2 8BJ,
UK

Andrew G Hadley
Divisional Manager, International Blood
Group Reference Laboratory, Southmead
Road, Bristol, BS10 5ND, UK
andrew.hadley@nbs.nhs.uk

Belinda Kumpel
Senior Research Scientist, Bristol Institute
for Transfusion Sciences, Southmead Road,
Bristol, BS10 5ND, UK
belinda.kumpel@nbs.nhs.uk

Geoff Lucas
Head of Platelet and Granulocyte
Immunology, International Blood Group
Reference Laboratory, Bristol, BS10 5ND,
UK
geoff.lucas@nbs.nhs.uk

Kenneth J Moise Jr
Professor of Obstetrics and Gynecology and
Director, Division of Maternal-Fetal
Medicine, University of North Carolina
School of Medicine, Chapel Hill, NC27599-
7570, USA
kmoisejr@med.unc.edu

xvi **List of contributors**

Michael F Murphy
Consultant Haematologist, National Blood Service and University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK
mike.murphy@nbs.nhs.uk

Geoff Poole
Head of Red Cell Immunohaematology, National Blood Service, Southmead Road, Bristol, BS10 5ND, UK
geoff.poole@nbs.nhs.uk

Rachel Rayment
Consultant Haematologist, National Blood Service, John Radcliffe Hospital, Oxford, OX3 9DU, UK

David Roberts
Consultant Haematologist, National Blood Service and University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK
david.roberts@nbs.nhs.uk

Glynn Russell
Consultant Neonatal Paediatrician, The Bristol Children’s Hospital, St Michael’s Hill, Bristol, BS2 8BJ, UK

Peter Soothill
Professor of Maternal and Fetal Medicine and Head of Obstetrics and Gynaecology, St Michael’s Hospital, Southwell Street, Bristol, BS2 8EG, UK
peter.soothill@bristol.ac.uk

Craig Turner
Research Scientist, Bristol Institute for Transfusion Sciences, Southmead Road, Bristol, BS10 5ND, UK
craig.turner@nbs.nhs.uk

Stan Urbaniak
Professor of Transfusion Medicine, Scottish National Blood Transfusion Service and University of Aberdeen, Royal National Infirmary, Foresterhill, Aberdeen, AB9 2ZW, UK
s.j.urbaniak@abdn.ac.uk

Paul W Whitecar
Fellow, Maternal-Fetal Medicine, Division of Maternal-Fetal Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7570, USA

Lorna M Williamson
Consultant Haematologist and Senior Lecturer, National Blood Service and University of Cambridge, Long Road, Cambridge, CB2 2PT, UK
lorna.williamson@nbs.nhs.uk

Preface

Definitions and terminology

The alloimmune cytopenias are a group of conditions in which the life span of fetal blood cells or their precursors is shortened by the action of antibodies derived from the mother by placental transfer. Three conditions are recognized: antibodies to fetal red cells, platelets or neutrophils, or their precursors, cause alloimmune anaemia, thrombocytopenia or neutropenia, respectively. Various terms are in common usage for these disorders, many of them inappropriate. For example, alloimmune anaemia is sometimes referred to as Rhesus disease, erythroblastosis fetalis or haemolytic disease of the newborn and all three are misnomers. It is incorrect to use 'Rhesus' to refer to the Rh system, fetal haemolysis may be caused by antibodies outside the Rh system, anaemia is not always associated with erythroblastosis and, finally, the disorder primarily affects the fetus rather than the newborn. Therefore, throughout this book, alloimmune anaemia (perhaps the best term) will be referred to as haemolytic disease of the fetus and newborn (HDFN). For similar reasons, alloimmune thrombocytopenia and alloimmune neutropenia will be used in preference to other terms, such as neonatal alloimmune thrombocytopenia, fetomaternal alloimmune thrombocytopenia and neonatal alloimmune neutropenia, while, at the same time, acknowledging that these terms are also commonly used.

The multidisciplinary approach to the management of the alloimmune cytopenias

The last 10 years of the 20th century saw significant advances in the management of alloimmunized pregnant women; immunologists made progress characterizing the molecular basis of the alloimmune response; molecular biologists solved the genetic basis for all the clinically important blood groups and developed DNA-based fetal typing assays; epidemiologists and health care economists developed a better understanding of the natural history of the alloimmune cytopenias and the

xviii Preface

cost-effectiveness of preventative programmes; obstetricians and fetal medicine specialists progressed the use of noninvasive fetal monitoring techniques; and haematologists improved the safety and efficacy of the various fetal transfusion therapies. With significant advances being made on so many fronts, the optimal prevention, diagnosis and management of alloimmunized pregnant women has become a team effort involving haematologists, obstetricians, paediatricians, immunologists, laboratory technicians in hospitals and transfusion centres, midwives and research scientists. However, it is rare for the individuals who contribute to this team effort to have a comprehensive overview of all the laboratory and clinical aspects associated with the alloimmune cytopenias.

Our intention in producing this book has been to bring the issues of pathogenesis, epidemiology, prevention, diagnosis and management together in a way which is both comprehensive and relevant to the various professionals involved. To this end, we have tried to avoid subspecialty jargon and to limit the use of abbreviations as far as possible because those used daily by laboratory scientists may be less familiar to clinicians and vice versa.

Andrew G Hadley
Peter Soothill

Foreword

This book is a very good idea. It brings together all the different aspects of the alloimmune cytopenias that are needed to understand them. The two most important are the red cell and the platelet cytopenias and they have features in common as well as characteristics that sharply differentiate them. For each condition, consideration is given to the genetics, the pathophysiology, the evidence for the efficacy and cost-effectiveness of screening and prevention, and to the management of the affected fetus and neonate. To have authoritative chapters on all these topics within the covers of one book is extremely helpful both for those who are new to these clinical problems and for those who, like the author of this foreword, have been grappling with them for over 20 years. The editors and their multidisciplinary team are to be congratulated and thanked for producing this valuable synthesis.

Professor Charles H Rodeck
Department of Obstetrics and Gynaecology
Royal Free and University College London Medical School

Abbreviations

ADCC	Antibody-dependent cell-mediated cytotoxicity
AMIS	Antibody-mediated immune suppression
ARMS	Amplification refractory mutation system
ASPA	Allele-specific primer amplification
C3	Third component of complement
CD	Cluster of differentiation
CLT	Chemiluminescence test
CMV	Cytomegalovirus
CTG	Cardiotocography
DAGT	Direct antiglobulin test
ELISA	Enzyme-linked immunosorbent assay
FBS	Fetal blood sampling
FcγR	Fc gamma receptor (receptor for the Fc domain of IgG)
GAT	Granulocyte agglutination test
GIFT	Granulocyte immunofluorescence test
HbsAg	Hepatitis B surface antigen
HCV	Hepatitis C virus
HIV	Human immunodeficiency virus
HPA	Human platelet antigen
HTLV	Human lymphotropic virus
IAGT	Indirect antiglobulin test
ICH	Intracranial haemorrhage
IL	Interleukin
Ig	Immunoglobulin
im	Intramuscularly
IU	International Units
IUT	Intrauterine transfusion
iv	Intravenously
IVIG	Intravenous immunoglobulin
Hb	Haemoglobin

xxii **List of abbreviations**

HDFN	Haemolytic disease of the fetus and newborn
HLA	Human leukocyte antigen or histocompatibility locus antigen
HPA	Human platelet antigen
HNA	Human neutrophil antigen
kD	Kilodalton
LISS	Low ionic strength saline
MAIGA	Monoclonal antibody immobilization of granulocyte antigens assay
MAIPA	Monoclonal antibody immobilization of platelet antigens assay
MMA	Monocyte monolayer assay
ΔOD_{450}	Optical density at a wavelength of 450 nm
PCR	Polymerase chain reaction
PEG	Polyethyleneglycol
PIFT	Platelet immunofluorescence test
RFLP	Restriction fragment length polymorphism
SNP	Single nucleotide polymorphism
TAV	Time-averaged mean velocity
TPH	Transplacental haemorrhage